We have now completed our journey across Denmark, Sweden, Finland and Norway.

Four countries.
Four distinct strengths.
One shared evidence philosophy.

Denmark – deeply integrated national registries and a strong epidemiological tradition
Sweden– clinically rich quality registries embedded in routine care
Finland – structured secondary-use frameworks […]

Norway closes our Nordic RWD series for a reason.
A universal healthcare system, personal identifiers, and decades of national coverage enable true longitudinal follow-up across care settings.

This is not just data availability.
It is […]

This is the third installment of the RWD sources from the Nordics. This week’s highlight is Finland’s real-world data ecosystem; which is built on something rare: continuity.

📆 Since the 1960s, nationwide health […]

Denmark offers one of the world’s most robust environments for real-world evidence generation. Key strengths include:

1️⃣ Fast access to comprehensive data
The average time to fully process applications at the Danish Health Data […]

Sweden’s RWD ecosystem is one of the most powerful globally — rich in coverage, high in trust, and fully linkable across registers via the personal identity number unique to every resident.

Thousands of […]

📅 On 26 November, Kelsi Smith, Senior Project Lead at Quantify Research, was invited to speak at an online webinar hosted by the Singapore Clinical Research Institute (SCRI) – Generating Real-World Evidence from Real-World […]

Last week, Quantify’s Head of RWE and Analytics Emilie Toresson Grip were invited to join 70+ leaders from healthcare, academia, and industry to the Swelife High-Level Meeting. The meeting aimed to discuss concrete solutions to health data challenges in Sweden in the […]

🩺 Real‑world diabetes research—done right
From risk prediction in metabolic syndrome to cost comparisons in insulin delivery, diabetes care needs rigour, relevance, and real‑world insight.

🔹 In 2024, we helped show how metabolic syndrome traits raise the risk of liver outcomes in […]

Managed Entry Agreements (MEAs) are important tools for reimbursement across Sweden, Norway, Denmark, and Finland – especially in areas such as oncology, rare diseases and precision medicine. While their use is growing, the pathways and requirements differ substantially between countries.
From […]

We asked our colleague Hannah Norman, Senior Project Leader in Market Access & HTA to share her experience.

💡What do project Leaders in Nordic Market Access and HTA actually do? “We help pharmaceutical companies bring life-saving and innovative medicines to market. […]